Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE LA 160 50 versus PINDAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERIDE LA 160 50 versus PINDAC.
INDERIDE LA 160/50 vs PINDAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propranolol: Non-selective beta-adrenergic receptor antagonist (blocks β1 and β2 receptors). Hydrochlorothiazide: Thiazide diuretic inhibiting Na+/Cl- cotransporter in distal convoluted tubule, reducing intravascular volume by increasing sodium and water excretion.
Vasodilator (arteriolar dilator) reducing afterload; also inhibits platelet aggregation through inhibition of phosphodiesterase III.
One capsule orally once daily. Each capsule contains propranolol hydrochloride 160 mg and hydrochlorothiazide 50 mg. Dosage should be individualized; typical maintenance dose is 1 capsule per day.
Oral: 2.5-5 mg twice daily; maximum 20 mg daily.
None Documented
None Documented
Propranolol: 3-6 hours (parent drug), 8-12 hours (4-hydroxypropranolol active metabolite) with prolonged half-life in hepatic impairment; Hydrochlorothiazide: 6-15 hours, extended in renal impairment (creatinine clearance <30 mL/min).
Terminal elimination half-life is 3-4 hours in healthy individuals, prolonged to 7-15 hours in renal impairment and in elderly patients. Clinical context: dosing interval adjustment recommended for CrCl <30 mL/min.
Propranolol: primarily hepatic metabolism to inactive metabolites, <1% excreted unchanged in urine; Hydrochlorothiazide: 50-70% excreted unchanged in urine, remainder as metabolites via renal and biliary routes.
Pindac (pindolol) is eliminated predominantly via hepatic metabolism (60-65%) with renal excretion of unchanged drug (35-40%). Less than 1% is excreted in feces via biliary elimination.
Category C
Category C
Beta Blocker
Beta Blocker